Analysts Estimate Castle Biosciences, Inc. (CSTL) to Report a Decline in Earnings: What to Look Out for

Core Viewpoint - Castle Biosciences, Inc. (CSTL) is expected to report a year-over-year decline in earnings and revenues for the quarter ended September 2025, with a consensus outlook indicating a quarterly loss of $0.34 per share and revenues of $71.3 million, down 16.9% from the previous year [1][3]. Earnings Expectations - The upcoming earnings report is anticipated to be released on November 3, and the stock may experience price movement based on whether the actual results exceed or fall short of expectations [2]. - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analyst expectations [4]. Earnings Surprise Prediction - The Most Accurate Estimate for Castle Biosciences aligns with the Zacks Consensus Estimate, resulting in an Earnings ESP of 0%, suggesting no recent differing analyst views [12]. - Despite the Earnings ESP of 0%, the stock holds a Zacks Rank of 1 (Strong Buy), which typically indicates a higher likelihood of an earnings beat [12]. Historical Performance - In the last reported quarter, Castle Biosciences was expected to post a loss of $0.51 per share but instead reported earnings of $0.15, resulting in a surprise of +129.41% [14]. - Over the past four quarters, the company has beaten consensus EPS estimates three times [15]. Industry Context - In the broader Zacks Medical - Biomedical and Genetics industry, Biogen Inc. (BIIB) is expected to report earnings of $3.89 per share for the same quarter, reflecting a year-over-year change of -4.7% and revenues of $2.34 billion, down 5.1% from the previous year [19][20].